1 Study Coverage
    1.1 Antihypertensive Product Introduction
    1.2 Market by Type
        1.2.1 Global Antihypertensive Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
        1.2.2 Diuretics
        1.2.3 Angiotensin Converting Enzyme (ACE) Inhibitors
        1.2.4 Angiotensin Receptor Blockers (ARBs)
        1.2.5 Calcium Channel Blockers
        1.2.6 Beta Blockers
        1.2.7 Alpha Blockers
        1.2.8 Vasodilators & Renin Inhibitors
    1.3 Market by Application
        1.3.1 Global Antihypertensive Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
        1.3.2 Hospital Pharmacy
        1.3.3 Retail Pharmacy
        1.3.4 Online Pharmacy
        1.3.5 Others
    1.4 Study Objectives
    1.5 Years Considered
2 Executive Summary
    2.1 Global Antihypertensive Sales Estimates and Forecasts 2017-2028
    2.2 Global Antihypertensive Revenue Estimates and Forecasts 2017-2028
    2.3 Global Antihypertensive Revenue by Region: 2017 VS 2021 VS 2028
    2.4 Global Antihypertensive Sales by Region
        2.4.1 Global Antihypertensive Sales by Region (2017-2022)
        2.4.2 Global Sales Antihypertensive by Region (2023-2028)
    2.5 Global Antihypertensive Revenue by Region
        2.5.1 Global Antihypertensive Revenue by Region (2017-2022)
        2.5.2 Global Antihypertensive Revenue by Region (2023-2028)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global Antihypertensive Sales by Manufacturers
        3.1.1 Global Top Antihypertensive Manufacturers by Sales (2017-2022)
        3.1.2 Global Antihypertensive Sales Market Share by Manufacturers (2017-2022)
        3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Antihypertensive in 2021
    3.2 Global Antihypertensive Revenue by Manufacturers
        3.2.1 Global Antihypertensive Revenue by Manufacturers (2017-2022)
        3.2.2 Global Antihypertensive Revenue Market Share by Manufacturers (2017-2022)
        3.2.3 Global Top 10 and Top 5 Companies by Antihypertensive Revenue in 2021
    3.3 Global Antihypertensive Sales Price by Manufacturers (2017-2022)
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Antihypertensive Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global Antihypertensive Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
    4.1 Global Antihypertensive Sales by Type
        4.1.1 Global Antihypertensive Historical Sales by Type (2017-2022)
        4.1.2 Global Antihypertensive Forecasted Sales by Type (2023-2028)
        4.1.3 Global Antihypertensive Sales Market Share by Type (2017-2028)
    4.2 Global Antihypertensive Revenue by Type
        4.2.1 Global Antihypertensive Historical Revenue by Type (2017-2022)
        4.2.2 Global Antihypertensive Forecasted Revenue by Type (2023-2028)
        4.2.3 Global Antihypertensive Revenue Market Share by Type (2017-2028)
    4.3 Global Antihypertensive Price by Type
        4.3.1 Global Antihypertensive Price by Type (2017-2022)
        4.3.2 Global Antihypertensive Price Forecast by Type (2023-2028)
5 Market Size by Application
    5.1 Global Antihypertensive Sales by Application
        5.1.1 Global Antihypertensive Historical Sales by Application (2017-2022)
        5.1.2 Global Antihypertensive Forecasted Sales by Application (2023-2028)
        5.1.3 Global Antihypertensive Sales Market Share by Application (2017-2028)
    5.2 Global Antihypertensive Revenue by Application
        5.2.1 Global Antihypertensive Historical Revenue by Application (2017-2022)
        5.2.2 Global Antihypertensive Forecasted Revenue by Application (2023-2028)
        5.2.3 Global Antihypertensive Revenue Market Share by Application (2017-2028)
    5.3 Global Antihypertensive Price by Application
        5.3.1 Global Antihypertensive Price by Application (2017-2022)
        5.3.2 Global Antihypertensive Price Forecast by Application (2023-2028)
6 North America
    6.1 North America Antihypertensive Market Size by Type
        6.1.1 North America Antihypertensive Sales by Type (2017-2028)
        6.1.2 North America Antihypertensive Revenue by Type (2017-2028)
    6.2 North America Antihypertensive Market Size by Application
        6.2.1 North America Antihypertensive Sales by Application (2017-2028)
        6.2.2 North America Antihypertensive Revenue by Application (2017-2028)
    6.3 North America Antihypertensive Market Size by Country
        6.3.1 North America Antihypertensive Sales by Country (2017-2028)
        6.3.2 North America Antihypertensive Revenue by Country (2017-2028)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe Antihypertensive Market Size by Type
        7.1.1 Europe Antihypertensive Sales by Type (2017-2028)
        7.1.2 Europe Antihypertensive Revenue by Type (2017-2028)
    7.2 Europe Antihypertensive Market Size by Application
        7.2.1 Europe Antihypertensive Sales by Application (2017-2028)
        7.2.2 Europe Antihypertensive Revenue by Application (2017-2028)
    7.3 Europe Antihypertensive Market Size by Country
        7.3.1 Europe Antihypertensive Sales by Country (2017-2028)
        7.3.2 Europe Antihypertensive Revenue by Country (2017-2028)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific Antihypertensive Market Size by Type
        8.1.1 Asia Pacific Antihypertensive Sales by Type (2017-2028)
        8.1.2 Asia Pacific Antihypertensive Revenue by Type (2017-2028)
    8.2 Asia Pacific Antihypertensive Market Size by Application
        8.2.1 Asia Pacific Antihypertensive Sales by Application (2017-2028)
        8.2.2 Asia Pacific Antihypertensive Revenue by Application (2017-2028)
    8.3 Asia Pacific Antihypertensive Market Size by Region
        8.3.1 Asia Pacific Antihypertensive Sales by Region (2017-2028)
        8.3.2 Asia Pacific Antihypertensive Revenue by Region (2017-2028)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America Antihypertensive Market Size by Type
        9.1.1 Latin America Antihypertensive Sales by Type (2017-2028)
        9.1.2 Latin America Antihypertensive Revenue by Type (2017-2028)
    9.2 Latin America Antihypertensive Market Size by Application
        9.2.1 Latin America Antihypertensive Sales by Application (2017-2028)
        9.2.2 Latin America Antihypertensive Revenue by Application (2017-2028)
    9.3 Latin America Antihypertensive Market Size by Country
        9.3.1 Latin America Antihypertensive Sales by Country (2017-2028)
        9.3.2 Latin America Antihypertensive Revenue by Country (2017-2028)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
10 Middle East and Africa
    10.1 Middle East and Africa Antihypertensive Market Size by Type
        10.1.1 Middle East and Africa Antihypertensive Sales by Type (2017-2028)
        10.1.2 Middle East and Africa Antihypertensive Revenue by Type (2017-2028)
    10.2 Middle East and Africa Antihypertensive Market Size by Application
        10.2.1 Middle East and Africa Antihypertensive Sales by Application (2017-2028)
        10.2.2 Middle East and Africa Antihypertensive Revenue by Application (2017-2028)
    10.3 Middle East and Africa Antihypertensive Market Size by Country
        10.3.1 Middle East and Africa Antihypertensive Sales by Country (2017-2028)
        10.3.2 Middle East and Africa Antihypertensive Revenue by Country (2017-2028)
        10.3.3 Turkey
        10.3.4 Saudi Arabia
11 Company Profiles
    11.1 Pfizer
        11.1.1 Pfizer Corporation Information
        11.1.2 Pfizer Overview
        11.1.3 Pfizer Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.1.4 Pfizer Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.1.5 Pfizer Recent Developments
    11.2 Norvatis
        11.2.1 Norvatis Corporation Information
        11.2.2 Norvatis Overview
        11.2.3 Norvatis Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.2.4 Norvatis Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.2.5 Norvatis Recent Developments
    11.3 Merck & Co.
        11.3.1 Merck & Co. Corporation Information
        11.3.2 Merck & Co. Overview
        11.3.3 Merck & Co. Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.3.4 Merck & Co. Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.3.5 Merck & Co. Recent Developments
    11.4 Sanofi
        11.4.1 Sanofi Corporation Information
        11.4.2 Sanofi Overview
        11.4.3 Sanofi Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.4.4 Sanofi Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.4.5 Sanofi Recent Developments
    11.5 AstraZeneca
        11.5.1 AstraZeneca Corporation Information
        11.5.2 AstraZeneca Overview
        11.5.3 AstraZeneca Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.5.4 AstraZeneca Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.5.5 AstraZeneca Recent Developments
    11.6 GSK
        11.6.1 GSK Corporation Information
        11.6.2 GSK Overview
        11.6.3 GSK Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.6.4 GSK Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.6.5 GSK Recent Developments
    11.7 Daiichi-Sankyo
        11.7.1 Daiichi-Sankyo Corporation Information
        11.7.2 Daiichi-Sankyo Overview
        11.7.3 Daiichi-Sankyo Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.7.4 Daiichi-Sankyo Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.7.5 Daiichi-Sankyo Recent Developments
    11.8 Boehringer-Ingelheim
        11.8.1 Boehringer-Ingelheim Corporation Information
        11.8.2 Boehringer-Ingelheim Overview
        11.8.3 Boehringer-Ingelheim Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.8.4 Boehringer-Ingelheim Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.8.5 Boehringer-Ingelheim Recent Developments
    11.9 Bayer
        11.9.1 Bayer Corporation Information
        11.9.2 Bayer Overview
        11.9.3 Bayer Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.9.4 Bayer Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.9.5 Bayer Recent Developments
    11.10 Johnson & Johnson
        11.10.1 Johnson & Johnson Corporation Information
        11.10.2 Johnson & Johnson Overview
        11.10.3 Johnson & Johnson Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.10.4 Johnson & Johnson Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.10.5 Johnson & Johnson Recent Developments
    11.11 Bristol-Myers Squibb
        11.11.1 Bristol-Myers Squibb Corporation Information
        11.11.2 Bristol-Myers Squibb Overview
        11.11.3 Bristol-Myers Squibb Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.11.4 Bristol-Myers Squibb Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.11.5 Bristol-Myers Squibb Recent Developments
    11.12 Tekeda
        11.12.1 Tekeda Corporation Information
        11.12.2 Tekeda Overview
        11.12.3 Tekeda Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.12.4 Tekeda Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.12.5 Tekeda Recent Developments
    11.13 Ranbaxy Laboratories
        11.13.1 Ranbaxy Laboratories Corporation Information
        11.13.2 Ranbaxy Laboratories Overview
        11.13.3 Ranbaxy Laboratories Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.13.4 Ranbaxy Laboratories Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.13.5 Ranbaxy Laboratories Recent Developments
    11.14 Shihuida Pharm
        11.14.1 Shihuida Pharm Corporation Information
        11.14.2 Shihuida Pharm Overview
        11.14.3 Shihuida Pharm Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.14.4 Shihuida Pharm Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.14.5 Shihuida Pharm Recent Developments
    11.15 Second Pharmaceutical
        11.15.1 Second Pharmaceutical Corporation Information
        11.15.2 Second Pharmaceutical Overview
        11.15.3 Second Pharmaceutical Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.15.4 Second Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.15.5 Second Pharmaceutical Recent Developments
    11.16 Lupin Limited.
        11.16.1 Lupin Limited. Corporation Information
        11.16.2 Lupin Limited. Overview
        11.16.3 Lupin Limited. Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.16.4 Lupin Limited. Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.16.5 Lupin Limited. Recent Developments
    11.17 Yangtze River Pharmaceutical
        11.17.1 Yangtze River Pharmaceutical Corporation Information
        11.17.2 Yangtze River Pharmaceutical Overview
        11.17.3 Yangtze River Pharmaceutical Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.17.4 Yangtze River Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.17.5 Yangtze River Pharmaceutical Recent Developments
    11.18 Hengrui Medicine
        11.18.1 Hengrui Medicine Corporation Information
        11.18.2 Hengrui Medicine Overview
        11.18.3 Hengrui Medicine Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.18.4 Hengrui Medicine Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.18.5 Hengrui Medicine Recent Developments
    11.19 Qilu Pharmaceutical
        11.19.1 Qilu Pharmaceutical Corporation Information
        11.19.2 Qilu Pharmaceutical Overview
        11.19.3 Qilu Pharmaceutical Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.19.4 Qilu Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.19.5 Qilu Pharmaceutical Recent Developments
    11.20 HUALON
        11.20.1 HUALON Corporation Information
        11.20.2 HUALON Overview
        11.20.3 HUALON Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.20.4 HUALON Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.20.5 HUALON Recent Developments
    11.21 Dawnrays
        11.21.1 Dawnrays Corporation Information
        11.21.2 Dawnrays Overview
        11.21.3 Dawnrays Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.21.4 Dawnrays Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.21.5 Dawnrays Recent Developments
    11.22 HISUN Pharmceutical
        11.22.1 HISUN Pharmceutical Corporation Information
        11.22.2 HISUN Pharmceutical Overview
        11.22.3 HISUN Pharmceutical Antihypertensive Sales, Price, Revenue and Gross Margin (2017-2022)
        11.22.4 HISUN Pharmceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
        11.22.5 HISUN Pharmceutical Recent Developments
12 Industry Chain and Sales Channels Analysis
    12.1 Antihypertensive Industry Chain Analysis
    12.2 Antihypertensive Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 Antihypertensive Production Mode & Process
    12.4 Antihypertensive Sales and Marketing
        12.4.1 Antihypertensive Sales Channels
        12.4.2 Antihypertensive Distributors
    12.5 Antihypertensive Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 Antihypertensive Industry Trends
    13.2 Antihypertensive Market Drivers
    13.3 Antihypertensive Market Challenges
    13.4 Antihypertensive Market Restraints
14 Key Findings in The Global Antihypertensive Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
                  
              

                

                 
List of Tables
    Table 1. Global Antihypertensive Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
    Table 2. Major Manufacturers of Diuretics
    Table 3. Major Manufacturers of Angiotensin Converting Enzyme (ACE) Inhibitors
    Table 4. Major Manufacturers of Angiotensin Receptor Blockers (ARBs)
    Table 5. Major Manufacturers of Calcium Channel Blockers
    Table 6. Major Manufacturers of Beta Blockers
    Table 7. Major Manufacturers of Alpha Blockers
    Table 8. Major Manufacturers of Vasodilators & Renin Inhibitors
    Table 9. Global Antihypertensive Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
    Table 10. Global Antihypertensive Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
    Table 11. Global Antihypertensive Sales by Region (2017-2022) & (K Units)
    Table 12. Global Antihypertensive Sales Market Share by Region (2017-2022)
    Table 13. Global Antihypertensive Sales by Region (2023-2028) & (K Units)
    Table 14. Global Antihypertensive Sales Market Share by Region (2023-2028)
    Table 15. Global Antihypertensive Revenue by Region (2017-2022) & (US$ Million)
    Table 16. Global Antihypertensive Revenue Market Share by Region (2017-2022)
    Table 17. Global Antihypertensive Revenue by Region (2023-2028) & (US$ Million)
    Table 18. Global Antihypertensive Revenue Market Share by Region (2023-2028)
    Table 19. Global Antihypertensive Sales by Manufacturers (2017-2022) & (K Units)
    Table 20. Global Antihypertensive Sales Share by Manufacturers (2017-2022)
    Table 21. Global Antihypertensive Revenue by Manufacturers (2017-2022) & (US$ Million)
    Table 22. Global Antihypertensive Revenue Share by Manufacturers (2017-2022)
    Table 23. Antihypertensive Price by Manufacturers (2017-2022) &(USD/Unit)
    Table 24. Global Antihypertensive Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 25. Global Antihypertensive by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antihypertensive as of 2021)
    Table 26. Antihypertensive Manufacturing Base Distribution and Headquarters
    Table 27. Manufacturers Antihypertensive Product Offered
    Table 28. Date of Manufacturers Enter into Antihypertensive Market
    Table 29. Mergers & Acquisitions, Expansion Plans
    Table 30. Global Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 31. Global Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 32. Global Antihypertensive Sales Share by Type (2017-2022)
    Table 33. Global Antihypertensive Sales Share by Type (2023-2028)
    Table 34. Global Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 35. Global Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 36. Global Antihypertensive Revenue Share by Type (2017-2022)
    Table 37. Global Antihypertensive Revenue Share by Type (2023-2028)
    Table 38. Antihypertensive Price by Type (2017-2022) & (USD/Unit)
    Table 39. Global Antihypertensive Price Forecast by Type (2023-2028) & (USD/Unit)
    Table 40. Global Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 41. Global Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 42. Global Antihypertensive Sales Share by Application (2017-2022)
    Table 43. Global Antihypertensive Sales Share by Application (2023-2028)
    Table 44. Global Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 45. Global Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 46. Global Antihypertensive Revenue Share by Application (2017-2022)
    Table 47. Global Antihypertensive Revenue Share by Application (2023-2028)
    Table 48. Antihypertensive Price by Application (2017-2022) & (USD/Unit)
    Table 49. Global Antihypertensive Price Forecast by Application (2023-2028) & (USD/Unit)
    Table 50. North America Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 51. North America Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 52. North America Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 53. North America Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 54. North America Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 55. North America Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 56. North America Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 57. North America Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 58. North America Antihypertensive Sales by Country (2017-2022) & (K Units)
    Table 59. North America Antihypertensive Sales by Country (2023-2028) & (K Units)
    Table 60. North America Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
    Table 61. North America Antihypertensive Revenue by Country (2023-2028) & (US$ Million)
    Table 62. Europe Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 63. Europe Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 64. Europe Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 65. Europe Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 66. Europe Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 67. Europe Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 68. Europe Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 69. Europe Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 70. Europe Antihypertensive Sales by Country (2017-2022) & (K Units)
    Table 71. Europe Antihypertensive Sales by Country (2023-2028) & (K Units)
    Table 72. Europe Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
    Table 73. Europe Antihypertensive Revenue by Country (2023-2028) & (US$ Million)
    Table 74. Asia Pacific Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 75. Asia Pacific Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 76. Asia Pacific Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 77. Asia Pacific Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 78. Asia Pacific Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 79. Asia Pacific Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 80. Asia Pacific Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 81. Asia Pacific Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 82. Asia Pacific Antihypertensive Sales by Region (2017-2022) & (K Units)
    Table 83. Asia Pacific Antihypertensive Sales by Region (2023-2028) & (K Units)
    Table 84. Asia Pacific Antihypertensive Revenue by Region (2017-2022) & (US$ Million)
    Table 85. Asia Pacific Antihypertensive Revenue by Region (2023-2028) & (US$ Million)
    Table 86. Latin America Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 87. Latin America Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 88. Latin America Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 89. Latin America Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 90. Latin America Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 91. Latin America Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 92. Latin America Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 93. Latin America Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 94. Latin America Antihypertensive Sales by Country (2017-2022) & (K Units)
    Table 95. Latin America Antihypertensive Sales by Country (2023-2028) & (K Units)
    Table 96. Latin America Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
    Table 97. Latin America Antihypertensive Revenue by Country (2023-2028) & (US$ Million)
    Table 98. Middle East and Africa Antihypertensive Sales by Type (2017-2022) & (K Units)
    Table 99. Middle East and Africa Antihypertensive Sales by Type (2023-2028) & (K Units)
    Table 100. Middle East and Africa Antihypertensive Revenue by Type (2017-2022) & (US$ Million)
    Table 101. Middle East and Africa Antihypertensive Revenue by Type (2023-2028) & (US$ Million)
    Table 102. Middle East and Africa Antihypertensive Sales by Application (2017-2022) & (K Units)
    Table 103. Middle East and Africa Antihypertensive Sales by Application (2023-2028) & (K Units)
    Table 104. Middle East and Africa Antihypertensive Revenue by Application (2017-2022) & (US$ Million)
    Table 105. Middle East and Africa Antihypertensive Revenue by Application (2023-2028) & (US$ Million)
    Table 106. Middle East and Africa Antihypertensive Sales by Country (2017-2022) & (K Units)
    Table 107. Middle East and Africa Antihypertensive Sales by Country (2023-2028) & (K Units)
    Table 108. Middle East and Africa Antihypertensive Revenue by Country (2017-2022) & (US$ Million)
    Table 109. Middle East and Africa Antihypertensive Revenue by Country (2023-2028) & (US$ Million)
    Table 110. Pfizer Corporation Information
    Table 111. Pfizer Description and Major Businesses
    Table 112. Pfizer Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 113. Pfizer Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 114. Pfizer Recent Developments
    Table 115. Norvatis Corporation Information
    Table 116. Norvatis Description and Major Businesses
    Table 117. Norvatis Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 118. Norvatis Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 119. Norvatis Recent Developments
    Table 120. Merck & Co. Corporation Information
    Table 121. Merck & Co. Description and Major Businesses
    Table 122. Merck & Co. Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 123. Merck & Co. Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 124. Merck & Co. Recent Developments
    Table 125. Sanofi Corporation Information
    Table 126. Sanofi Description and Major Businesses
    Table 127. Sanofi Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 128. Sanofi Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 129. Sanofi Recent Developments
    Table 130. AstraZeneca Corporation Information
    Table 131. AstraZeneca Description and Major Businesses
    Table 132. AstraZeneca Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 133. AstraZeneca Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 134. AstraZeneca Recent Developments
    Table 135. GSK Corporation Information
    Table 136. GSK Description and Major Businesses
    Table 137. GSK Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 138. GSK Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 139. GSK Recent Developments
    Table 140. Daiichi-Sankyo Corporation Information
    Table 141. Daiichi-Sankyo Description and Major Businesses
    Table 142. Daiichi-Sankyo Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 143. Daiichi-Sankyo Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 144. Daiichi-Sankyo Recent Developments
    Table 145. Boehringer-Ingelheim Corporation Information
    Table 146. Boehringer-Ingelheim Description and Major Businesses
    Table 147. Boehringer-Ingelheim Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 148. Boehringer-Ingelheim Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 149. Boehringer-Ingelheim Recent Developments
    Table 150. Bayer Corporation Information
    Table 151. Bayer Description and Major Businesses
    Table 152. Bayer Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 153. Bayer Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 154. Bayer Recent Developments
    Table 155. Johnson & Johnson Corporation Information
    Table 156. Johnson & Johnson Description and Major Businesses
    Table 157. Johnson & Johnson Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 158. Johnson & Johnson Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 159. Johnson & Johnson Recent Developments
    Table 160. Bristol-Myers Squibb Corporation Information
    Table 161. Bristol-Myers Squibb Description and Major Businesses
    Table 162. Bristol-Myers Squibb Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 163. Bristol-Myers Squibb Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 164. Bristol-Myers Squibb Recent Developments
    Table 165. Tekeda Corporation Information
    Table 166. Tekeda Description and Major Businesses
    Table 167. Tekeda Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 168. Tekeda Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 169. Tekeda Recent Developments
    Table 170. Ranbaxy Laboratories Corporation Information
    Table 171. Ranbaxy Laboratories Description and Major Businesses
    Table 172. Ranbaxy Laboratories Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 173. Ranbaxy Laboratories Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 174. Ranbaxy Laboratories Recent Developments
    Table 175. Shihuida Pharm Corporation Information
    Table 176. Shihuida Pharm Description and Major Businesses
    Table 177. Shihuida Pharm Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 178. Shihuida Pharm Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 179. Shihuida Pharm Recent Developments
    Table 180. Second Pharmaceutical Corporation Information
    Table 181. Second Pharmaceutical Description and Major Businesses
    Table 182. Second Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 183. Second Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 184. Second Pharmaceutical Recent Developments
    Table 185. Lupin Limited. Corporation Information
    Table 186. Lupin Limited. Description and Major Businesses
    Table 187. Lupin Limited. Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 188. Lupin Limited. Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 189. Lupin Limited. Recent Developments
    Table 190. Yangtze River Pharmaceutical Corporation Information
    Table 191. Yangtze River Pharmaceutical Description and Major Businesses
    Table 192. Yangtze River Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 193. Yangtze River Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 194. Yangtze River Pharmaceutical Recent Developments
    Table 195. Hengrui Medicine Corporation Information
    Table 196. Hengrui Medicine Description and Major Businesses
    Table 197. Hengrui Medicine Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 198. Hengrui Medicine Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 199. Hengrui Medicine Recent Developments
    Table 200. Qilu Pharmaceutical Corporation Information
    Table 201. Qilu Pharmaceutical Description and Major Businesses
    Table 202. Qilu Pharmaceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 203. Qilu Pharmaceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 204. Qilu Pharmaceutical Recent Developments
    Table 205. HUALON Corporation Information
    Table 206. HUALON Description and Major Businesses
    Table 207. HUALON Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 208. HUALON Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 209. HUALON Recent Developments
    Table 210. Dawnrays Corporation Information
    Table 211. Dawnrays Description and Major Businesses
    Table 212. Dawnrays Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 213. Dawnrays Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 214. Dawnrays Recent Developments
    Table 215. HISUN Pharmceutical Corporation Information
    Table 216. HISUN Pharmceutical Description and Major Businesses
    Table 217. HISUN Pharmceutical Antihypertensive Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2017-2022)
    Table 218. HISUN Pharmceutical Antihypertensive Product Model Numbers, Pictures, Descriptions and Specifications
    Table 219. HISUN Pharmceutical Recent Developments
    Table 220. Key Raw Materials Lists
    Table 221. Raw Materials Key Suppliers Lists
    Table 222. Antihypertensive Distributors List
    Table 223. Antihypertensive Customers List
    Table 224. Antihypertensive Market Trends
    Table 225. Antihypertensive Market Drivers
    Table 226. Antihypertensive Market Challenges
    Table 227. Antihypertensive Market Restraints
    Table 228. Research Programs/Design for This Report
    Table 229. Key Data Information from Secondary Sources
    Table 230. Key Data Information from Primary Sources
List of Figures
    Figure 1. Antihypertensive Product Picture
    Figure 3. Global Antihypertensive Market Share by Type in 2021 & 2028
    Figure 3. Diuretics Product Picture
    Figure 4. Angiotensin Converting Enzyme (ACE) Inhibitors Product Picture
    Figure 5. Angiotensin Receptor Blockers (ARBs) Product Picture
    Figure 6. Calcium Channel Blockers Product Picture
    Figure 7. Beta Blockers Product Picture
    Figure 8. Alpha Blockers Product Picture
    Figure 9. Vasodilators & Renin Inhibitors Product Picture
    Figure 10. Global Antihypertensive Market Share by Application in 2021 & 2028
    Figure 11. Hospital Pharmacy
    Figure 12. Retail Pharmacy
    Figure 13. Online Pharmacy
    Figure 14. Others
    Figure 15. Antihypertensive Report Years Considered
    Figure 16. Global Antihypertensive Sales 2017-2028 (K Units)
    Figure 17. Global Antihypertensive Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 18. Global Antihypertensive Revenue 2017-2028 (US$ Million)
    Figure 19. Global Antihypertensive Revenue Market Share by Region in Percentage: 2021 Versus 2028
    Figure 20. Global Antihypertensive Sales Market Share by Region (2017-2022)
    Figure 21. Global Antihypertensive Sales Market Share by Region (2023-2028)
    Figure 22. North America Antihypertensive Sales YoY (2017-2028) & (K Units)
    Figure 23. North America Antihypertensive Revenue YoY (2017-2028) & (US$ Million)
    Figure 24. Europe Antihypertensive Sales YoY (2017-2028) & (K Units)
    Figure 25. Europe Antihypertensive Revenue YoY (2017-2028) & (US$ Million)
    Figure 26. Asia-Pacific Antihypertensive Sales YoY (2017-2028) & (K Units)
    Figure 27. Asia-Pacific Antihypertensive Revenue YoY (2017-2028) & (US$ Million)
    Figure 28. Latin America Antihypertensive Sales YoY (2017-2028) & (K Units)
    Figure 29. Latin America Antihypertensive Revenue YoY (2017-2028) & (US$ Million)
    Figure 30. Middle East & Africa Antihypertensive Sales YoY (2017-2028) & (K Units)
    Figure 31. Middle East & Africa Antihypertensive Revenue YoY (2017-2028) & (US$ Million)
    Figure 32. The Antihypertensive Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
    Figure 33. The Top 5 and 10 Largest Manufacturers of Antihypertensive in the World: Market Share by Antihypertensive Revenue in 2021
    Figure 34. Global Antihypertensive Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
    Figure 35. Global Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 36. Global Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 37. Global Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 38. Global Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 39. North America Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 40. North America Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 41. North America Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 42. North America Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 43. North America Antihypertensive Sales Share by Country (2017-2028)
    Figure 44. North America Antihypertensive Revenue Share by Country (2017-2028)
    Figure 45. U.S. Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 46. Canada Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 47. Europe Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 48. Europe Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 49. Europe Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 50. Europe Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 51. Europe Antihypertensive Sales Share by Country (2017-2028)
    Figure 52. Europe Antihypertensive Revenue Share by Country (2017-2028)
    Figure 53. Germany Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 54. France Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 55. U.K. Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 56. Italy Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 57. Russia Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 58. Asia Pacific Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 59. Asia Pacific Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 60. Asia Pacific Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 61. Asia Pacific Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 62. Asia Pacific Antihypertensive Sales Share by Region (2017-2028)
    Figure 63. Asia Pacific Antihypertensive Revenue Share by Region (2017-2028)
    Figure 64. China Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 65. Japan Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 66. South Korea Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 67. India Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 68. Australia Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 69. Taiwan Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 70. Indonesia Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 71. Thailand Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 72. Malaysia Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 73. Philippines Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 74. Latin America Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 75. Latin America Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 76. Latin America Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 77. Latin America Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 78. Latin America Antihypertensive Sales Share by Country (2017-2028)
    Figure 79. Latin America Antihypertensive Revenue Share by Country (2017-2028)
    Figure 80. Mexico Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 81. Brazil Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 82. Argentina Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 83. Middle East and Africa Antihypertensive Sales Market Share by Type (2017-2028)
    Figure 84. Middle East and Africa Antihypertensive Revenue Market Share by Type (2017-2028)
    Figure 85. Middle East and Africa Antihypertensive Sales Market Share by Application (2017-2028)
    Figure 86. Middle East and Africa Antihypertensive Revenue Market Share by Application (2017-2028)
    Figure 87. Middle East and Africa Antihypertensive Sales Share by Country (2017-2028)
    Figure 88. Middle East and Africa Antihypertensive Revenue Share by Country (2017-2028)
    Figure 89. Turkey Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 90. Saudi Arabia Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 91. U.A.E Antihypertensive Revenue (2017-2028) & (US$ Million)
    Figure 92. Antihypertensive Value Chain
    Figure 93. Antihypertensive Production Process
    Figure 94. Channels of Distribution
    Figure 95. Distributors Profiles
    Figure 96. Bottom-up and Top-down Approaches for This Report
    Figure 97. Data Triangulation
    Figure 98. Key Executives Interviewed